These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30568177)

  • 41. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
    Capoluongo E; Ellison G; López-Guerrero JA; Penault-Llorca F; Ligtenberg MJL; Banerjee S; Singer C; Friedman E; Markiefka B; Schirmacher P; Büttner R; van Asperen CJ; Ray-Coquard I; Endris V; Kamel-Reid S; Percival N; Bryce J; Röthlisberger B; Soong R; de Castro DG
    Semin Oncol; 2017 Jun; 44(3):187-197. PubMed ID: 29248130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
    Lheureux S; Braunstein M; Oza AM
    CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 44. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
    Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Olaparib Keeps Hereditary Breast Tumors in Check.
    Cancer Discov; 2017 Aug; 7(8):OF10. PubMed ID: 28583909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Markowski MC; Antonarakis ES
    J Clin Oncol; 2020 Nov; 38(32):3735-3739. PubMed ID: 32870734
    [No Abstract]   [Full Text] [Related]  

  • 49. Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
    Ashworth A; Lord CJ
    Nat Rev Clin Oncol; 2018 Sep; 15(9):564-576. PubMed ID: 29955114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
    Kurnit KC; Fleming GF; Lengyel E
    Obstet Gynecol; 2021 Jan; 137(1):108-121. PubMed ID: 33278287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Chan JK; Liang SY; Kapp DS; Chan JE; Herzog TJ; Coleman RL; Monk BJ; Richardson MT
    Gynecol Oncol; 2020 Dec; 159(3):604-606. PubMed ID: 32994055
    [No Abstract]   [Full Text] [Related]  

  • 52. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
    Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of niraparib for the treatment of ovarian cancer.
    Ethier JL; Lheureux S; Oza AM
    Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management and Treatment of Recurrent Epithelial Ovarian Cancer.
    Armbruster S; Coleman RL; Rauh-Hain JA
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):965-982. PubMed ID: 30390768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Lavie O; Chetrit A; Novikov I; Sadetzki S;
    Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
    de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
    Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.